Journal article
Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study
Future oncology (London, England), Vol.20(22), pp.1553-1563
07/11/2024
DOI: 10.2217/fon-2023-1064
PMCID: PMC11457592
PMID: 38629593
Abstract
To assess real-world clinical outcomes with standard therapies for advanced non-small-cell lung cancer (aNSCLC) with METexon14 skipping mutation (METex14).
In an oncologists-led retrospective review of medical records, data were abstracted and analyzed for patients initiating first-line (1L) systemic therapy after 1 January 2017.
In total 287 aNSCLC patients with METex14, the real-world best overall response rate was 73.4% for capmatinib (n = 146), 68.8% for immunotherapy (IO) monotherapy (n = 48), 52.0% for chemotherapy (CT, n = 30), and 54.8% for IO + CT (n = 63). As compared with capmatinib, patients receiving IO (hazard ratio [HR]: 1.57; 95% CI: 0.77-3.20; p = 0.220), CT (HR: 2.41; 95% CI: 1.19-4.85; p = 0.014) and IO + CT (HR: 2.33; 95% CI: 1.35-4.04; p = 0.003) had higher rates of progression. Further, patients receiving CT (HR: 4.43; 95% CI: 1.54-12.75; p = 0.006) and IO + CT (HR: 3.53, 95% CI: 1.41-8.85; p = 0.007) had higher rates of mortality than patients receiving capmatinib.
The study showed better clinical outcomes with capmatinib than other standard therapies in 1L setting for aNSCLC harboring METex14.
Details
- Title: Subtitle
- Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study
- Creators
- Muhammad Furqan - University of Iowa Hospitals and ClinicsSiddharth Karanth - RTI Health SolutionsRavi K Goyal - RTI Health SolutionsBeilei Cai - NovartisJulien Rombi - RTI Health SolutionsKeith L Davis - RTI Health SolutionsNydia Caro - NovartisTeddy Saliba - Novartis
- Resource Type
- Journal article
- Publication Details
- Future oncology (London, England), Vol.20(22), pp.1553-1563
- DOI
- 10.2217/fon-2023-1064
- PMID
- 38629593
- PMCID
- PMC11457592
- NLM abbreviation
- Future Oncol
- ISSN
- 1479-6694
- eISSN
- 1479-6694
- Grant note
- Novartis Pharmaceuticals Corporation
- Language
- English
- Electronic publication date
- 04/17/2024
- Date published
- 07/11/2024
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984586459202771
Metrics
3 Record Views